Sermorelin Acetate
GHRH(1-29) · GRF 1-29 · Geref
Think of it as a gentle wake-up call for your body's growth hormone.
Sermorelin Acetate is like a nudge for your pituitary gland, encouraging it to naturally release more growth hormone. Instead of directly adding extra hormones into your system, it prompts your body to do what it already knows how to do, but maybe isn't doing as well as it used to.
This peptide can help bring back some of that youthful growth hormone rhythm that tends to fade as we age. It's a bit like reminding your body how it used to operate when you were younger. Some studies even suggest it might help you get more of that deep, restorative sleep that leaves you feeling refreshed.
Originally, Sermorelin was used to test kids' growth hormone levels, but now it's more about supporting adults who want to tap into their body's own growth potential without resorting to synthetic hormones.
Who it's for
- Adults looking to boost their natural growth hormone levels.
- People interested in supporting their body's aging process naturally.
- Those who want to improve sleep quality with more deep sleep.
Probably not for you if…
- Anyone looking for a quick fix with synthetic growth hormones.
- Individuals not comfortable with injections.
- Those expecting dramatic overnight results.
Editorial summary for research context · Not medical advice
Mechanism of Action
Sermorelin is a 29-amino-acid synthetic analog representing the bioactive N-terminal fragment of endogenous GHRH. It binds GHRH receptors on pituitary somatotrophs to stimulate synthesis and pulsatile release of growth hormone. Because it acts upstream of the pituitary and relies on intact negative feedback via somatostatin, it preserves physiologic GH pulsatility and is self-limiting compared to exogenous HGH. Plasma half-life is short (approximately 10-20 minutes). Formerly FDA-approved as Geref for pediatric GH deficiency diagnostics; that approval was withdrawn in 2008 for commercial reasons, not safety.
Researched Benefits
Physiologic GH axis stimulation
Research has shown Sermorelin restores age-related decline in GH pulse amplitude while preserving feedback regulation.
- [Walker 2006]
Sleep architecture
Evening administration has been associated with increased slow-wave sleep in small clinical studies of GH-deficient adults.
- [Vitiello et al. 2006]
Diagnostic utility
Historically used as a provocative test of pituitary GH reserve in pediatric endocrinology.
Research Protocols
The following dosing ranges have appeared in published research protocols. Presented for informational purposes only — not a recommendation for human use.
Standard research protocol
- Dosage
- 300 mcg
- Frequency
- once daily
- Timing
- pre-bed, fasted
- Cycle
- 12 weeks
Research protocols have used 200-500mcg subcutaneous nightly. Long cycles (3-6 months) are common given the modest per-dose effect.
Sermorelin + GHRP research stack
- Dosage
- 200 mcg
- Frequency
- once daily
- Timing
- pre-bed
- Cycle
- 12 weeks
Paired with GHRP-2 or GHRP-6 (100-200mcg) for synergistic GH release — GHRH analog + ghrelin mimetic is a classic research combination.
Reported Side Effects
- Injection-site reactions (redness, swelling)
- Transient flushing and warmth post-injection
- Headache (infrequent)
- Dysphagia or dysgeusia reported rarely
Contraindications
- Active malignancy
- Pregnancy and lactation
- Known hypersensitivity to GHRH analogs
- Severe obesity may blunt response
Stacking Partners
Peptides commonly paired with Sermorelin Acetate in published research and protocol write-ups.
Vendor Pricing
Stacked earns a commission on purchases via these links. It does not influence our Trust Scores.
Gear + Companions
Reconstitution supplies and research-backed supplement companions for Sermorelin Acetate. Editorial picks only — we earn a commission through Amazon on the click, no sponsorship.
Gear you'll need
· Reconstitution + storage essentialsBacteriostatic Water 30mL (0.9% Benzyl Alcohol)
Empower Pharmacy / generic medical supply
Reconstitutes every lyophilized peptide. 28-day viability refrigerated.
Insulin Syringes 31G × 5/16" × 0.5mL (100 count)
EasyTouch
31G × 0.5mL insulin syringes — the default size for sub-0.25mL peptide doses.
Alcohol Prep Pads (Sterile, 200 count)
Dynarex
Sterile 70% IPA prep pads — one per vial stopper + one per injection site.
1-Quart Sharps Disposal Container
BD / Becton Dickinson
FDA-cleared sharps container — pharmacies won't accept improvised disposal.
Stacks well with
· Supplement companions — independent evidence, not sponsoredCreatine Monohydrate Powder 1kg
BulkSupplements
Creatine + GH-axis peptides increase lean-mass signaling via different pathways (IGF-1 + phosphocreatine replenishment). Most-studied stack in the literature.
Whey Protein Isolate 5 lb (Grass-Fed, Unflavored)
NAKED Nutrition
Growth-hormone-axis research is substrate-limited — without adequate protein intake the signaling can't translate to tissue.
As an Amazon Associate we earn from qualifying purchases · Disclosed per FTC guidelines
Top Videos
Curated from YouTube — refreshed weekly. Stacked doesn't host or endorse external content.
16:43Sermorelin & Ibutamoren (MK-677) - HGH Secretagogues - Doc's Analysis of Side Effects & Properties
Testosteronology® Health Portal / Anabolic Doc
401.3K views · 16:43 · 6 years ago
7:15Doctor Explains Your RISK of Cancer From Popular Peptides
This Is Not Covered - Dr. Ashley Froese
173.1K views · 7:15 · 5 months ago
10:21The Truth About Peptides | Do They Really Burn Fat?
Joey Thurman
134.1K views · 10:21 · 4 years ago
5:53CJC and Sermorelin EXPLAINED | Why these peptides are so POWERFUL💥
The Novus Center
119K views · 5:53 · 3 years ago
7:21SERMORELIN PEPTIDE / Explain This with Robin Riddle, NP-C
Performance Medicine
95.4K views · 7:21 · 4 years ago
Research Papers
Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Walker RF · Clinical Interventions in Aging · 2006
PubMed 18046911 →Growth hormone-releasing hormone or growth hormone treatment in older men alters body composition
Vitiello MV, et al. · Journals of Gerontology, Series A · 2006
PubMed 17167154 →




